Camparison of tab bilastine vs tab levovetrizine in treatment of urticaria

A randomized control study comparing efficacy and safety of tab bilastine 20 mg vs tab levocetrizine 5 mg in acute and chronic urticaria

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/12/030117

Enrollment

Registered

2020-12-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L509- Urticaria, unspecified

Interventions

Intervention1: Tab bilastine 20 mg: One group will be given 20 mg tab bilastine once a day before dinner for 8 weeks Control Intervention1: Tab levocetrizine 5 mg: Other group will be given tab levoce

Eligibility

Inclusion criteria

Inclusion criteria: Patients of urticaria aged 15-80 years willimg to give consent will be imcluded in study

Exclusion criteria

Exclusion criteria: Patients with urticarial vsculitis, senile pruritus, drug induced urticaria will be excluded. Patients with hypersensitivity to drug will be excluded. Pregnant and lactating females will be excluded

Design outcomes

Primary

Measure	Time frame
Urticaria activity score Patient global assessment scoreTimepoint: At baseline and then every 2 weeks for 8 weeks	—

Secondary

Measure	Time frame
Any adverse drug event will be notifiedTimepoint: At 8 weeks	—

Countries

India

Contacts

Public ContactDr shreya somani

Government medical.college bhavnagar

hitamehta88@gmail.com9429503188

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026